NDAINTRAMUSCULAR, INTRAVENOUSINJECTABLEPriority Review
Approved
Dec 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
4/8 — Partial
Priority Review
ROCEPHIN (ceftriaxone sodium) by Roche is clinical pharmacology average plasma concentrations of ceftriaxone following a single 30-minute intravenous (iv) infusion of a 0. First approved in 1984.
Drug data last refreshed 2d ago
Mechanism of Action
CLINICAL PHARMACOLOGY Average plasma concentrations of ceftriaxone following a single 30-minute intravenous (IV) infusion of a 0.5, 1 or 2 g dose and intramuscular (IM) administration of a single 0.5 (250 mg/mL or 350 mg/mL concentrations) or 1 g dose in healthy subjects are presented in Table 1 .…
Worked on ROCEPHIN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.